
ljubaphoto/E+ via Getty Images
Eli Lilly’s (LLY) Zepbound helped adolescents with obesity or excess weight and related health conditions achieve substantial weight reductions in a new study, supporting the company’s push to expand the medicine’s use to younger patients.
The 160 participants, whose average starting